Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN)

Langhorne, PA – September 27, 2025 – Investors in NEXGEL Inc. (NASDAQ: NXGL), a company at the forefront of hydrogel technology, are closely watching the trajectory of its equity warrants (NXGLW). While NEXGEL has demonstrated impressive revenue growth and expanding gross margins, its persistent unprofitability and a recent "going concern" disclosure have

Kenvue (NYSE: KVUE), the consumer health giant spun off from Johnson & Johnson, has experienced a significant rebound in its stock price, climbing notably from a recent record low. This resurgence comes after a period of intense pressure, primarily fueled by controversial, unproven claims linking its flagship Tylenol product to neurodevelopmental

Haleon (HLN​​​​​​​) is one of the largest consumer health companies in the world. Over the past year, Haleon PLC share price rose 13.8% from $7.60 to $8.66 as of Tuesday’s market close.

KKR is closing in on a $2.9B takeover of Karo Healthcare after outbidding rivals, reinforcing its aggressive push into European healthcare.

Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's largest shareholder with over 5%.

Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains weighted to the second half.

Dr. Reddy's Q3 FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS.

Pfizer's 2025 guidance to be revealed Tuesday. Goldman Sachs predicts $64.9 billion revenue and EPS of $3.13, supported by Paxlovid and Eliquis growth.

Kenvue Inc. (NYSE:KVUE) shares are moving higher Monday following a report suggesting activist investor Starboard Value has acquired a stake in the company.

Elf Beauty appeared to rally along with KVUE on Monday.

Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on innovative medicines and vaccines.

Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company.

Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks arrange debt financing for potential buyers.

Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in.

Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for £500 million ($632 million). This strategic move allows Haleon to focus on growth areas.

Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.

GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advil painkillers.

Pfizer to reduce stake in Haleon to approximately 24% following earlier divestment announcement. Offer price per share to be revealed post book-building process by Haleon.

Haleon reports FY 2023 revenue growth of 4.1% to £11.3 billion ($14.03 billion), missing consensus. Adjusted operating profit rises 10.4% to £2.55 billion. CEO Brian McNamara outlines solid financial discipline, a £500 million share buyback plan for 2024, and reaffirms 2024 growth targets.